Updated April 23, 2020 The most commonly prescribed treatment for lupus, hydroxychloroquine (best known as Plaquenil) is not effective for treating COVID-19 according to a new study of 368 hospitalized patients in United States Veteran Administration medical centers. Led by Mr. Joseph Magagnoli, Dr. Siddharth Narendran and Dr. Felipe Pereira at University of South Carolina, […] READ MORE
April 20,2020 The Lupus Research Alliance is proud to share that the COVID-19 Global Rheumatology Alliance, of which the organization is a sponsor, has gathered and published in record time data on 110 people with lupus or another rheumatic disease who also have COVID-19. The paper appeared in the highly prestigious medical journal The Lancet […] READ MORE
April 16, 2020 A recently published study led by Dr. Gregg Dinse provides compelling evidence that proteins found in many people with autoimmune diseases have become more common in Americans over time. Using blood samples taken from 14,211 people representative of the American population, the researchers found that these proteins, also known as anti-nuclear antibodies […] READ MORE
April 16, 2020 Treating people with lupus earlier with belimumab (Benlysta) may work better than as a last option according to a study just published in the well-respected journal Arthritis & Rheumatology Researchers in Italy analyzed data from 466 people with lupus at 24 centers in Italy who were receiving belimumab intravenously. They looked at […] READ MORE
April 16, 2020 The Lupus Research Alliance is pleased to share news that promises to speed up testing and review of a potential new treatment for lupus. The U.S. Food and Drug Administration granted fast-track designation to RC18, in development by a company in China, RemeGen. The FDA defines fast track as “a process designed […] READ MORE
April 12, 2020 Today, the Lupus Research Alliance (LRA) Scientific Advisory Board Chair Dr. Gary Koretzky emailed top federal health officials a strong letter calling attention to concerns about availability of hydroxychloroquine for patients with systemic lupus erythematosus. The letter was addressed to: Alex M. Azar II, JD, Secretary, Health and Human Services; Stephen […] READ MORE
8 de abril de 2020 Estimado amigo de Lupus Research Alliance: Como sabrá, debido a la posibilidad de que Plaquenil (hidroxicloroquina) sea útil para tratar la COVID-19, se ha generado una importante escasez que dificulta en gran medida que los pacientes con lupus que dependen del medicamento resurtan sus recetas. Si bien esta escasez es más […] READ MORE
New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA), announced today that it is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus. The study […] READ MORE
7 de abril de 2020 Nueva York, NY, 7 de abril de 2020 – Lupus Therapeutics, la filial de ensayos clínicos de Lupus Research Alliance (LRA), anunció hoy que está iniciando un estudio clínico para evaluar el posible beneficio de la hidroxicloroquina u otras terapias para el lupus con el fin de evitar o […] READ MORE
April 3, 2020 The Lupus Research Alliance (LRA) hosted a live webcast April 2, 2020 on COVID-19 for people with lupus that you won’t want to miss – so click here to view the full video recording. The webast addressed the most frequently asked questions doctors are hearing from people with lupus, put the hydroxychloroquine […] READ MORE
April 3, 2020 The President and CEO of the LRA, Kenneth Farber wrote personally to Speaker Nancy Pelosi and Leader Kevin McCarthy in the House of Representatives and Leader Mitch McConnell and Leader Chuck Schumer in the Senate asking that “any COVID-19 response and recovery package include provisions to ensure lupus patients maintain access to […] READ MORE
April 1, 2020 An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants. Results were reported in Arthritis Research & Therapy. The small study included 14 patients with refractory lupus nephritis. Each were […] READ MORE
